Literature DB >> 35611388

HIV co-infection augments EBV-induced tumorigenesis in vivo.

Christopher B Whitehurst1,2, Monica Rizk3,4,5, Adonay Teklezghi3,4,5, Rae Ann Spagnuolo3,4,5, Joseph S Pagano1,2,6, Angela Wahl3,4,5.   

Abstract

In most individuals, EBV maintains a life-long asymptomatic latent infection. However, EBV can induce the formation of B cell lymphomas in immune suppressed individuals including people living with HIV (PLWH). Most individuals who acquire HIV are already infected with EBV as EBV infection is primarily acquired during childhood and adolescence. Although antiretroviral therapy (ART) has substantially reduced the incidence of AIDS-associated malignancies, EBV positive PLWH are at an increased risk of developing lymphomas compared to the general population. The direct effect of HIV co-infection on EBV replication and EBV-induced tumorigenesis has not been experimentally examined. Using a humanized mouse model of EBV infection, we demonstrate that HIV co-infection enhances systemic EBV replication and immune activation. Importantly, EBV-induced tumorigenesis was augmented in EBV/HIV co-infected mice. Collectively, these results demonstrate a direct effect of HIV co-infection on EBV pathogenesis and disease progression and will facilitate future studies to address why the incidence of certain types of EBV-associated malignancies are stable or increasing in ART treated PLWH.

Entities:  

Keywords:  B cell lymphoma; EBV; HIV; co-infection; humanized mice; replication; tumorigenesis

Year:  2022        PMID: 35611388      PMCID: PMC9126505          DOI: 10.3389/fviro.2022.861628

Source DB:  PubMed          Journal:  Front Virol        ISSN: 2673-818X


  39 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

2.  Changes in the composition of circulating CD8+ T cell subsets during acute epstein-barr and human immunodeficiency virus infections in humans.

Authors:  M T Roos; R A van Lier; D Hamann; G J Knol; I Verhoofstad; D van Baarle; F Miedema; P T Schellekens
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

3.  Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy.

Authors:  Paul D Ling; Regis A Vilchez; Wendy A Keitel; David G Poston; Rong Sheng Peng; Zoe S White; Fehmida Visnegarwala; Dorothy E Lewis; Janet S Butel
Journal:  Clin Infect Dis       Date:  2003-09-23       Impact factor: 9.079

4.  A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses.

Authors:  Misako Yajima; Ken-Ichi Imadome; Atsuko Nakagawa; Satoru Watanabe; Kazuo Terashima; Hiroyuki Nakamura; Mamoru Ito; Norio Shimizu; Mitsuo Honda; Naoki Yamamoto; Shigeyoshi Fujiwara
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

5.  Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.

Authors:  H J Delecluse; T Hilsendegen; D Pich; R Zeidler; W Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

6.  T cells establish and maintain CNS viral infection in HIV-infected humanized mice.

Authors:  Jenna B Honeycutt; Baolin Liao; Christopher C Nixon; Rachel A Cleary; William O Thayer; Shayla L Birath; Michael D Swanson; Patricia Sheridan; Oksana Zakharova; Francesca Prince; JoAnn Kuruc; Cynthia L Gay; Chris Evans; Joseph J Eron; Angela Wahl; J Victor Garcia
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

7.  EBV and HIV-Related Lymphoma.

Authors:  Michele Bibas; Andrea Antinori
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-29       Impact factor: 2.576

8.  Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.

Authors:  Angela Wahl; Phong T Ho; Paul W Denton; Katy L Garrett; Michael G Hudgens; Glenn Swartz; Cynthia O'Neill; Fulvia Veronese; Angela D Kashuba; J Victor Garcia
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

9.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.

Authors:  Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

10.  Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads.

Authors:  Catherine M Byrne; Christine Johnston; Jackson Orem; Fred Okuku; Meei-Li Huang; Habibur Rahman; Anna Wald; Lawrence Corey; Joshua T Schiffer; Corey Casper; Daniel Coombs; Soren Gantt
Journal:  PLoS Comput Biol       Date:  2021-06-21       Impact factor: 4.475

View more
  1 in total

Review 1.  Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses.

Authors:  Tania H Mulherkar; Daniel Joseph Gómez; Grace Sandel; Pooja Jain
Journal:  Viruses       Date:  2022-09-14       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.